Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy
- Conditions
- Peanut Allergy
- Interventions
- Biological: Viaskin Peanut 250mcgBiological: Placebo
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- DBV Technologies
- Target Recruit Count
- 356
- Registration Number
- NCT02636699
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Medical Center of Dallas, Dallas, Texas, United States
🇨🇦Gordon Sussman Clinical Research Inc., Toronto, Ontario, Canada
Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy
- Conditions
- Food Allergy
- Interventions
- Biological: Viaskin Milk 300 mcgBiological: Viaskin Milk 150 mcgBiological: Viaskin Milk 500 mcgBiological: Viaskin Placebo
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- DBV Technologies
- Target Recruit Count
- 198
- Registration Number
- NCT02223182
- Locations
- 🇺🇸
Children's Medical Center of Dallas, Dallas, Texas, United States
🇨🇦Cheema Research Inc., Mississauga, Ontario, Canada
🇨🇦Gordon Sussman Clinical Research Inc., Toronto, Ontario, Canada
Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
- Conditions
- Peanut Allergy
- Interventions
- Biological: Viaskin Peanut 250 mcg
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- DBV Technologies
- Target Recruit Count
- 171
- Registration Number
- NCT01955109
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇨🇦Cheema Research Inc., Mississauga, Ontario, Canada
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy
- Conditions
- Peanut Allergy
- Interventions
- Biological: Viaskin Peanut 250 mcgBiological: Viaskin Peanut 100 mcgBiological: Viaskin Peanut 50 mcgBiological: Viaskin Placebo
- First Posted Date
- 2012-08-30
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- DBV Technologies
- Target Recruit Count
- 221
- Registration Number
- NCT01675882
- Locations
- 🇫🇷
Nouvel Hôpital Civil, Strasbourg, France
🇫🇷Hôpitaux De Brabois, Vandoeuvre-les-Nancy, France
🇺🇸University of California, Rady Childrens Hospital, San Diego, California, United States
Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy
- Conditions
- Peanut Allergy
- Interventions
- Biological: Whole peanut extractBiological: Placebo formulation
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2012-03-23
- Lead Sponsor
- DBV Technologies
- Target Recruit Count
- 100
- Registration Number
- NCT01170286
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸National Jewish Health, Denver, Colorado, United States